University of Minnesota. Driven to Discover.
It's approved for complicated UTIs caused by gram-negative bacteria—with a caveat.
The FDA recommends screening donor stool for multidrug-resistant organisms. Problem is, the procedures aren't uniform.
Experts underscore "pull" incentives to boost profits.
The drug, which was FDA-approved last month, went toe to toe with moxifloxacin.
The FDA proposes a 2-year implementation period after it finalizes the guidance.
A letter argues that the EPA has ignored other federal agencies and scientific evidence.
Lefamulin approval was supported by two phase 3 trials involving moxifloxacin.
The shorter, simpler regimen with the new drug is poised to improve treatment against a difficult disease and to lower costs.
The report shows a substantial drop in the use of nearly all medically important antibiotics from 2013 to 2017.
CMS will boost payments for the use of new antibiotics and for treating patients who have drug-resistant infections.
Sort Results By:
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.